arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Altimmune, Inc.

ALT
$1.97 ▼ -0.15 (-7.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Altimmune, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $365.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -4.1% ↗
FCF / Share $-0.13 ↗
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$26.00K
↑ +420.0% —
Net Income Profit after all expenses
$-22.56M
↓ -15.3% —
Operating Margin Operating profit as % of sales
-464.8%
↓ -40.8% —
FCF / Share Free cash flow per share
$-0.13
↑ +44.9% —
Long-Term Debt Long-term obligations
$34.74M
↑ +0.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
19
Financial Health ↑
45
Cash Quality ↓
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters